tiprankstipranks
Nuvectis Pharma initiates Phase 1b study for NXP800
The Fly

Nuvectis Pharma initiates Phase 1b study for NXP800

Nuvectis Pharma announced the initiation of the Phase 1b study for NXP800 in platinum-resistant, ARID1a-mutated ovarian carcinoma. The Phase 1b study is a multicenter, single-agent, open-label clinical trial of NXP800 in patients with platinum-resistant, ARID1a-mutated ovarian cancer, a tumor type that is comprised almost exclusively of ovarian clear-cell carcinoma and ovarian endometrioid carcinoma. The study will examine the safety, tolerability and preliminary efficacy of NXP800 in this target patient population. The study will enroll two cohorts of up to approximately 25 patients each and will evaluate two dosing regimens, 50 mg and 75 mg, administered once daily, selected based on data from the Phase 1a dose escalation study in patients with various types of advanced solid tumors. The study will be conducted in 25-30 sites in the United States, United Kingdom and Europe in collaboration with the European Network of Gynaecological Oncological Trial Groups and the GOG Foundation, Inc., recognized as the world’s premier gynecology oncology clinical trials consortia. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the U.S. Food and Drug Administration.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NVCT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles